Tools

LEADER 03171cam 2200565 i 4500

001 on1243270141;

003 OCoLC;

005 20210412074756.0;

006 m o d f ;

007 cr |||||||||||;

008 210325s2021 dcu ob f000 0 eng c;

024 8 a| 38-120q| (GPO jacket number);

042 a| pcc;

043 a| n-us---;

049 a| ERE#;

050 4 a| KF27b| .E553 2019g;

074 a| 1019-C-01 (online);

086 0 a| Y 4.C 73/8:116-17;

088 a| Serial no. 116-17 (United States. Congress. House. Committee on Energy and Commerce);

245 10 a| Lowering the cost of prescription drugs :b| reducing barriers to market competition : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Sixteenth Congress, first session, March 13, 2019.;

264 1 a| Washington :b| U.S. Government Publishing Office,c| 2021.;

300 a| 1 online resource (vi, 246 pages).;

336 a| textb| txt2| rdacontent;

337 a| computerb| c2| rdamedia;

338 a| online resourceb| cr2| rdacarrier;

500 a| Access ID (govinfo): CHRG-116hhrg38120.;

500 a| "Serial no. 116-17.";

500 a| GPO Cataloging Record Distribution Program (CRDP).;

504 a| Includes bibliographical references.;

511 0 a| Hearing witnesses: Lou Kennedy, Chief Executive Officer and Owner, Nephron Pharmaceuticals; Chester ``Chip'' Davis, Jr., President and Chief Executive Officer, Association for Accessible Medicines; Anthony A. Barrueta, Senior Vice President, Government Relations, Kaiser Permanente; Marc M. Boutin, Chief Executive Officer, National Health Council; Kurt R. Karst, Director, Hyman, Phelps and McNamara, P. C; Jeffrey P. Kushan, Partner, Sidley Austin, LLP; Michael A. Carrier, Distinguished Professor, Rutgers Law School.;

518 a| Date of hearing: 2019-03-13.;

588 a| Description based on online resource; title from PDF title page (govinfo, viewed Mar. 25, 2021).;

650 0 a| Prescription pricingz| United Statesx| Public opinion.=| ^A5242;

650 0 a| Drugsx| Law and legislationz| United States.=| ^A639;

650 0 a| Drugsz| United Statesx| Patents.=| ^A640;

650 0 a| Patent laws and legislationz| United States.=| ^A64049;

650 0 a| Competitionz| United States.=| ^A113889;

650 0 a| Pharmaceutical industryz| United States.=| ^A638;

655 7 a| Legislative hearings.2| lcgft;

776 08 i| Print version:a| United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.t| Lowering the cost of prescription drugsw| (OCoLC)1243270284;

856 40 u| https://purl.fdlp.gov/GPO/gpo153433;

922 a| GOVINFOHRG;

922 a| BIBCONEWb| 20210325;

949 a| Click on web addressw| asish| joyner94;

596 a| 1;

998 a| 5581265;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5581265-1001l| JNETm| JOYNERr| Ys| Yt| JNE1DOu| 4/9/2021x| EDOCUMENTz| JERESOURCE;

Lowering the cost of prescription drugs : reducing barriers to market competition : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Sixteenth Congress, first session, March 13, 2019.

Author/creator	United States
Format	Electronic
Publication	Washington : U.S. Government Publishing Office, 2021.
Description	1 online resource (vi, 246 pages).
Supplemental Content	https://purl.fdlp.gov/GPO/gpo153433
Subjects	Prescription pricing--United States. --Public opinion. Drugs--Generic substitution. --Law and legislation. --United States. Drugs--Law and legislation. --United States. Drugs--United States. --Patents. Patent laws and legislation--United States. Competition--United States. Pharmaceutical industry--United States.

General note	Access ID (govinfo): CHRG-116hhrg38120.
General note	"Serial no. 116-17."
General note	GPO Cataloging Record Distribution Program (CRDP).
Bibliography note	Includes bibliographical references.
Performer	Hearing witnesses: Lou Kennedy, Chief Executive Officer and Owner, Nephron Pharmaceuticals; Chester ``Chip'' Davis, Jr., President and Chief Executive Officer, Association for Accessible Medicines; Anthony A. Barrueta, Senior Vice President, Government Relations, Kaiser Permanente; Marc M. Boutin, Chief Executive Officer, National Health Council; Kurt R. Karst, Director, Hyman, Phelps and McNamara, P. C; Jeffrey P. Kushan, Partner, Sidley Austin, LLP; Michael A. Carrier, Distinguished Professor, Rutgers Law School.
Date/time/place of a event note	Date of hearing: 2019-03-13.
Source of description	Description based on online resource; title from PDF title page (govinfo, viewed Mar. 25, 2021).
Issued in other form	Print version: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Lowering the cost of prescription drugs
Genre/form	Legislative hearings.
Standard identifier#	38-120 (GPO jacket number)
Technical rpt number	Serial no. 116-17 (United States. Congress. House. Committee on Energy and Commerce)
GPO item number	1019-C-01 (online)
Govt. docs number	Y 4.C 73/8:116-17

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Lowering the cost of prescription drugs : reducing barriers to market competition : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Sixteenth Congress, first session, March 13, 2019.

Click here for more information about this title

Availability